12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ProHema: Phase II halted

Fate disclosed in an S-1 filing that it paused enrollment in an open-label, U.S. Phase II trial comparing ProHema plus an unmanipulated cord blood unit vs. 2 unmanipulated cord blood units in patients undergoing...

Read the full 148 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >